ProPhase Labs (NASDAQ:PRPH) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a research report issued on Saturday. The firm set a “sell” rating on the stock.

ProPhase Labs Stock Performance

PRPH opened at $0.26 on Friday. The stock has a market cap of $6.28 million, a P/E ratio of -0.21 and a beta of -0.30. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The firm has a fifty day moving average price of $0.65 and a 200 day moving average price of $1.75. ProPhase Labs has a 1 year low of $0.26 and a 1 year high of $7.48.

Institutional Investors Weigh In On ProPhase Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sheets Smith Wealth Management acquired a new stake in ProPhase Labs in the 4th quarter worth about $158,000. HighTower Advisors LLC raised its stake in ProPhase Labs by 18.3% in the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after purchasing an additional 27,673 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in ProPhase Labs by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after purchasing an additional 13,590 shares in the last quarter. Hedge funds and other institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.